Work

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw372.02

Authors: J.S. de Bono, U. De Giorgi, C. Massard, S. Bracarda, D. Nava Rodrigues, I. Kocak, A. Font, J. Arranz Arija, K. Shih, G.D. Radavoi, W. Yu, W. Chan, S. Gendreau, L. Zhang, R. Riisnaes, M.J. Wongchenko, D. Maslyar, V. Jinga

Institutions: Institute of Cancer Research, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Institut Gustave Roussy, Ospedale San Donato, Masaryk Memorial Cancer Institute, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Hospital General Universitario Gregorio Marañón, Tennessee Oncology, Carol Davila University of Medicine and Pharmacy, Genentech

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2588340304

FWCI: 13.41

Cites:

Cited by: 52

Related to: 10